Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Invibio, Part of Victrex plc, Announces New Collaboration With Paragon Medical to Support Scale Up of PEEK Based Trauma Devices

Invibio Biomaterial Solutions, part of Victrex plc, a pioneer in the development of PEEK biomaterial solutions, today announced a new collaboration with Paragon Medical, a medical device contract design manufacturer with over a century of combined expertise in high-precision manufacturing, advanced engineering and design support, to manufacture composite PEEK-OPTIMA™ Ultra-Reinforced medical trauma devices.

The manufacturing arrangement with Paragon Medical will support the scale up of high quality PEEK-OPTIMA™ ultra-reinforced composite fracture fixation devices, at a time when Invibio is seeing demand exceeding initial expectations.

The announcement coincides with Paragon Medical’s recent expansion of dedicated space for this collaboration in their manufacturing facility in Changzhou, China.

Investing in the future of Invibio PEEK-OPTIMA™ Ultra-Reinforced composite devices

Invibio has extensive experience in collaborating with customers in PEEK-OPTIMA™ Ultra-Reinforced part design and process development, with significant know-how and intellectual property (IP). During this time Invibio has developed novel materials and IP in relation to optimising the design and development of these parts and supporting customers with regulatory approval.

“We are delighted to be working with Invibio to increase production of their innovative devices which can help to drive improved patient outcomes globally,” says Wil Boren, Paragon Medical CEO.

Providing scale, quality, confidence and manufacturing flexibility

The recent opening of the Invibio Leeds orthopedic product development centre in the UK has the potential to support an increase in the speed at which medical device companies can develop new PEEK-OPTIMA™ Ultra-Reinforced composite fracture fixation devices.

The Paragon Medical collaboration can provide Invibio customers with additional world class medical composite manufacturing facilities to help serve growing customer demand for these products.

“Trauma is one of Victrex’s key mega-programmes, where we see significant growth opportunities over the years ahead and the opportunity to enhance patient outcomes. Clinical data on PEEK based trauma plates is already encouraging and initial demand is exceeding our expectations. We have invested over several years now, and bring a wealth of intellectual property in this area. Paragon Medical will help us support manufacturing scale up, and they bring an excellent reputation as one of the world’s premier medical contract manufacturers. We are delighted to work with them to grow the composite trauma space and to make it easier for medical device companies to adopt this technology,” explains Jakob Sigurdsson, CEO of Victrex.

“With a broad operating footprint in Europe, China and America, Paragon Medical are an attractive company to work with, dealing with evolving supply chain strategies within the medical device industry.”

PEEK-OPTIMA™ Ultra-Reinforced composite device benefits

Patient risk factors affecting fracture healing such as diabetes, osteoporosis or obesity have increased significantly in recent years, which has in turn increased the challenges for traditional titanium plates and nails to successfully heal patients. The increased risk of delayed union or non-union may be reduced by utilising plates made from PEEK-OPTIMA™ Ultra-Reinforced materials due to their increased fatigue lifetime and the ability to tailor the stiffness of the device.*

PEEK based medical devices have been successfully implanted for over twenty years. The benefits of PEEK OPTIMA Ultra reinforced trauma plates such as increased fatigue lifetime, tailored stiffness and improved imaging are now being utilised to treat a more challenging patient population.*

The potential to reduce revisions and accelerate healing make these solutions attractive to surgeons, patients and to payors.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy